Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-3_05-md-01699/USCOURTS-cand-3_05-md-01699-108/pdf.json

Nature of Suit Code: 365
Nature of Suit: Personal Injury - Product Liability
Cause of Action: 28:1332 Diversity-Product Liability

---

DLA PIPER RUDNICK 

GRAY CARY US LLP 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-1- 

SD\1664256.3 

13415-401 STIP. & [PROPOSED] ORDER RE: PAGE LIMITS & DEADLINE FOR REPLIES ON 

MOTS. TO DISMISS PURCHASE CLAIMS MASTER COMPL. – M:05-CV-01699-CRB 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

IN RE: BEXTRA AND CELEBREX 

MARKETING SALES PRACTICES AND 

PRODUCT LIABILITY LITIGATION 

CASE NO. M:05-CV-01699-CRB 

MDL No. 1699 

This Order Relates to: 

 PURCHASE CLAIMS. 

STIPULATION AND [PROPOSED] 

ORDER REGARDING PAGE LIMITS AND 

FILING DEADLINE FOR REPLY BRIEFS 

ON PFIZER ENTITIES’ MOTIONS TO 

DISMISS PURCHASE CLAIMS MASTER 

COMPLAINTS 

1. Pursuant to Pretrial Order No. 7, certain plaintiffs have filed the “Purchase 

Claims Master Celebrex Complaint” and the “Purchase Claims Master Bextra Complaint” 

(collectively, “Master Complaints”). The Master Complaints aggregate 146 pages and assert 

numerous claims under the laws of several different states, as well as federal law. 

2. On March 29, 2006, the parties stipulated that memoranda in support of 

and in opposition to the Pfizer Defendants’ motions to dismiss the Master Complaints could not 

exceed eighty pages in aggregate. 

3. The Pfizer Defendants’ memoranda in support of the motions to dismiss 

the Master Complaints, excluding tables of contents and authorities and additional signature 

pages, totaled sixty-two pages: forty-four pages for the motion to dismiss the Purchase Claims 

///// 

Case 3:05-md-01699-CRB Document 346 Filed 05/30/06 Page 1 of 3
DLA PIPER RUDNICK 

GRAY CARY US LLP 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-2- 

SD\1664256.3 

13415-401 STIP. & [PROPOSED] ORDER RE: PAGE LIMITS & DEADLINE FOR REPLIES ON 

MOTS. TO DISMISS PURCHASE CLAIMS MASTER COMPL. – M:05-CV-01699-CRB 

Master Celebrex Complaint and eighteen pages for the motion to dismiss the Purchase Claims 

Master Bextra Complaint. 

4. The plaintiffs’ memoranda in opposition to the Pfizer Defendants’ motion 

to dismiss, excluding tables of contents and authorities and additional signature pages, totaled 

eighty pages: fifty-two pages for the opposition to the motion to dismiss the Purchase Claims 

Master Celebrex Complaint and twenty-eight pages for the opposition to the motion to dismiss 

the Purchase Claims Master Bextra Complaint. 

5. In the March 29, 2006 stipulation, the parties agreed to consider the 

appropriate length of reply memoranda after the opposition memoranda were filed. 

6. In light of the length of the Master Complaints and the memoranda in 

support of and in opposition to the Pfizer Defendants’ motions to dismiss, the parties hereby 

stipulate that relief from the page limits for reply briefs stated in the Local Rules is warranted in 

this proceeding. The Pfizer Defendants’ briefs in support of their motions to dismiss the Master 

Complaints shall not exceed forty-five (45) pages in the aggregate, excluding tables of contents 

and authorities and additional signature pages. This page limitation may be allocated between the 

reply brief in support of the motion directed to the Purchase Claims Master Celebrex Complaint 

and the reply brief in support of the motion directed to the Purchase Claims Master Bextra 

Complaint as the Pfizer Defendants deem necessary to state their positions without needless 

duplication. To the extent arguments apply to both Master Complaints, those arguments need not 

be repeated in the reply briefs but may be incorporated by reference. 

///// 

///// 

///// 

///// 

///// 

///// 

///// 

///// 

Case 3:05-md-01699-CRB Document 346 Filed 05/30/06 Page 2 of 3
DLA PIPER RUDNICK 

GRAY CARY US LLP 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

-3- 

SD\1664256.3 

13415-401 STIP. & [PROPOSED] ORDER RE: PAGE LIMITS & DEADLINE FOR REPLIES ON 

MOTS. TO DISMISS PURCHASE CLAIMS MASTER COMPL. – M:05-CV-01699-CRB 

7. The Pfizer Defendants must e-file their reply briefs by 9:00 a.m. Pacific on 

Tuesday, May 30. 

IT IS SO STIPULATED. 

Dated: May 26, 2006 LIEFF CABRASER HEIMANN & BERNSTEIN LLP 

By /s/ 

 ELIZABETH J. CABRASER 

Plaintiffs’ Liaison Counsel 

Dated: May 26, 2006 DLA PIPER RUDNICK GRAY CARY US LLP 

By /s/ 

 AMY W. SCHULMAN 

 Defendants’ Liaison Counsel 

PURSUANT TO STIPULATION, IT IS SO ORDERED. 

Dated: _________________, 2006 

HONORABLE CHARLES R. BREYER 

UNITED STATES DISTRICT JUDGE 

May 30

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORN

I

A

IT IS SO ORDERED

Judge Charles R. Breyer

Case 3:05-md-01699-CRB Document 346 Filed 05/30/06 Page 3 of 3